Benefit of GenSight’s gene therapy not so clear – BioPharma Dive
|
Benefit of GenSight's gene therapy not so clear
BioPharma Dive GenSight Biologics SA on April 3 announced topline results from the Phase 3 REVERSE trial that evaluated a single, intravitreal injection of its gene therapy candidate GS010 in 37 subjects with an inherited, degenerative eye disease who began losing … |
